These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27180669)

  • 1. [XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
    Edelsberger T
    Vnitr Lek; 2016 Mar; 62(3):199-201. PubMed ID: 27180669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New fixed combination in type 2 diabetes].
    Red
    MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
    Hu J; Zou P; Zhang S; Zhou M; Tan X
    Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
    Med Lett Drugs Ther; 2014; 56(1457):124-5. PubMed ID: 25461230
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes?
    Jabbour S
    Expert Opin Pharmacother; 2014 Dec; 15(18):2751-2. PubMed ID: 25346092
    [No Abstract]   [Full Text] [Related]  

  • 6. Dapagliflozin--do we need it registered for type 2 diabetes?
    Doggrell SA; Tuli R
    Expert Opin Pharmacother; 2014 Aug; 15(11):1631-5. PubMed ID: 24998153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):88. PubMed ID: 32555117
    [No Abstract]   [Full Text] [Related]  

  • 9. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 11. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP
    Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects.
    Khomitskaya Y; Tikhonova N; Gudkov K; Erofeeva S; Holmes V; Dayton B; Davies N; Boulton DW; Tang W
    Clin Ther; 2018 Apr; 40(4):550-561.e3. PubMed ID: 29548719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
    Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
    Tahrani AA
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
    de Bruin TW; Reele S; Hamer-Maansson JE; Parikh S; Tang W
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):118-30. PubMed ID: 27138025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.